RANDOMIZED, MULTICENTER TACROLIMUS WITH STEROID VS STEROID FREE (SNS-01)

随机、多中心他克莫司含类固醇与不含类固醇 (SNS-01)

• 批准号: 7607268
• 负责人: WILLIAM E. HARMON
• 金额: $ 2.39万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607268
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Daclizumab; Funding; Grant; Institution; Prograf; Protocols documentation; Randomized; Research; Research Personnel; Resources; Safety; Source; Standards of Weights and Measures; Steroids; Tacrolimus; Transplantation; United States National Institutes of Health; base; fluorouracil/methotrexate/mitoxantrone protocol; mycophenolate mofetil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study objective is to compare the safety and efficacy of a traditional steroid based-protocol (Prograf, MMF, steroids and standard daclizumab induction until the second month post-transplant) to a steroid-free protocol (Prograf, MMF and daclizumab induction until the sixth month post-transplant).

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较传统的基于类固醇方案(直到移植后2个月的Prograf、MMF、类固醇和标准的Daclizumab诱导)和非类固醇方案(直到移植后6个月的Prograf、MMF和Daclizumab诱导)的安全性和有效性。